Targeting IGF‐1/IGF‐1R signaling has been explored as a therapeutic strategy, with IGF‐1R inhibitors showing potential in insulin‐resistant cancers, particularly in breast, colorectal, and prostate cancer [22, 84]. This evidence concerns the gene IGF1R and prostate carcinoma.